Stockreport

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small...

NovoCure Limited - Ordinary Shares  (NVCR) 
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
PDF The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 mon [Read more]